---
title: "NMRA.US (NMRA.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/NMRA.US/news.md"
symbol: "NMRA.US"
name: "NMRA.US"
parent: "https://longbridge.com/zh-CN/quote/NMRA.US.md"
datetime: "2026-03-17T23:27:03.587Z"
locales:
  - [en](https://longbridge.com/en/quote/NMRA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NMRA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NMRA.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/NMRA.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/NMRA.US/news.md)


# NMRA.US (NMRA.US) — 相关新闻

### [17:31 ETDrug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight](https://longbridge.com/zh-CN/news/276796435.md)
*2026-02-24T22:32:17.000Z*
> DelveInsight forecasts significant growth in the drug-resistant epilepsy market from 2025 to 2034, driven by rising prev

### [Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment](https://longbridge.com/zh-CN/news/276161520.md)
*2026-02-17T19:32:20.000Z*
> William Blair upgraded Neumora Therapeutics (NASDAQ:NMRA) to Outperform, citing a favorable risk/reward after positive P

### [](https://longbridge.com/zh-CN/news/276154247.md)
*2026-02-17T17:44:58.000Z*
> Neumora Therapeutics shares are trading higher after William Blair upgraded the stock from Market Perform to Outperform 

### [Neumora Therapeutics (NASDAQ:NMRA) Rating Increased to Outperform at William Blair](https://longbridge.com/zh-CN/news/276123029.md)
*2026-02-17T12:26:50.000Z*
> William Blair upgraded Neumora Therapeutics (NASDAQ:NMRA) from a "market perform" to an "outperform" rating. Other analy

### [Neumora Therapeutics Highlights NMRA-511 AD Agitation Signal, Maps Higher-Dose Plan for 2026](https://longbridge.com/zh-CN/news/275982928.md)
*2026-02-14T15:04:21.000Z*
> Neumora Therapeutics (NASDAQ: NMRA) presented new clinical analyses for NMRA-511 targeting Alzheimer’s disease (AD) agit

### [Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora](https://longbridge.com/zh-CN/news/275644413.md)
*2026-02-11T18:15:30.000Z*
> Needham analyst Ami Fadia has maintained a Buy rating on Neumora Therapeutics, Inc. with a price target of $8.00, citing

### [Strengthening NMRA-511 Clinical Profile and Upside Potential Underpin Buy Rating and $18 Target](https://longbridge.com/zh-CN/news/275642425.md)
*2026-02-11T17:35:20.000Z*
> H.C. Wainwright analyst Douglas Tsao has reiterated a Buy rating for NMRA stock, setting a target price of $18. This bul

### [Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative?](https://longbridge.com/zh-CN/news/275638594.md)
*2026-02-11T17:02:07.000Z*
> Neumora Therapeutics presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026, aiming to enhance its

### [Neumora Therapeutics unveils new pipeline targeting neuropsychiatric and metabolic diseases](https://longbridge.com/zh-CN/news/275602847.md)
*2026-02-11T12:14:23.000Z*
### [](https://longbridge.com/zh-CN/news/275523066.md)
*2026-02-10T23:10:14.000Z*
> The Nasdaq Biotechnology Index fell by more than 1.2%. Among them, Medpace dropped 15.90%, Tectonic Therapeutic fell 15.